Gene therapy applications demonstrate therapeutic potential in hereditary spastic paraplegia (HSP) models, where ARL6IP1 restoration rescues ER–mitochondria homeostasis through LC3B/BCl2L13 interactions, ameliorating HSP‐associated pathophysiology [245]. The gene discussed is MAP1LC3B; the disease is hereditary spastic paraplegia.